Vanderbilt Center for Neuroscience Drug Discovery
Vanderbilt, Boehringer Ingelheim announce partnership to develop therapies for psychiatric disorders
Jan. 3, 2019—Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors known to engage in the modulation of certain brain circuitries, which are altered in neuropsychiatric conditions such as schizophrenia.
Lindsley named to National Academy of Inventors
Dec. 11, 2018—Craig W. Lindsley, William K. Warren Jr. Professor of Medicine and co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been elected a fellow of the prestigious National Academy of Inventors.
Ancora announces major funding awards to support Vanderbilt drug discovery research
Nov. 26, 2018—Ancora Innovation, LLC, the new collaboration between Vanderbilt and Deerfield Management established earlier this year, has completed its inaugural proposal review process and announced two projects selected for funding.
AAAS, chemistry society honor Lindsley’s research contributions
Feb. 1, 2018—Craig Lindsley, PhD, co-director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), has been named a fellow of the Royal Society of Chemistry and elected chair-elect of the Section of Pharmaceutical Sciences of the American Association for the Advancement of Science (AAAS).
Investigators eye new target for treating movement disorders
Jan. 18, 2018—Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson’s disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.
Lindsley honored by Pharmaceutical Society of Japan
Dec. 7, 2017—Craig Lindsley, PhD, the William K. Warren Jr. Professor of Medicine at Vanderbilt, is the 2018 recipient of the Sato Memorial International Award of the Pharmaceutical Society of Japan.
Award honors Conn’s mental health research contributions
Oct. 12, 2017—P. Jeffrey Conn, Ph.D., founding director of the Vanderbilt Center for Neuroscience Drug Discovery, has won a 2017 Research & Hope Award from the Pharmaceutical Research and Manufacturers of America (PhRMA) for outstanding research in the area of mental health.
University of Kansas honors Lindsley’s pharmacology research
Sep. 21, 2017—Craig Lindsley, Ph.D., co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been honored by the University of Kansas with the 2018 Edward E. Smissman Lectureship for his outstanding contributions to the fields of medicinal chemistry and molecular pharmacology.
Drug discovery efforts may lead to new Rett syndrome treatments
Aug. 24, 2017—Vanderbilt University research-ers have relieved symptoms of Rett syndrome in a mouse model with a small molecule that works like the dimmer switch in an electrical circuit.
Investigational new drug for Alzheimer’s scheduled for first study in humans
Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
Researchers eye potential schizophrenia ‘switch’
Sep. 15, 2016—Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.
Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt
Aug. 15, 2016—Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.